Navigation Links
PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Date:4/14/2009

was the primary endpoint of the IMPACT trial. The positive results from this landmark study provide confirmatory evidence demonstrating that treatment with PROVENGE may prolong survival," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We are immensely grateful to our clinical investigators and the more than 1,000 men with advanced prostate cancer who have participated in our studies over the last decade and whose courage and contribution have significantly advanced the understanding and treatment of prostate cancer and the potential role of cancer immunotherapies."

"The successful outcome from the Phase 3 IMPACT study provides validation of the long-pursued goal of harnessing the human immune system against a patient's own cancer," continued Dr. Gold.

Because the data meet the criteria and specifications outlined in its Special Protocol Assessment (SPA) agreement with the FDA, Dendreon intends to file an amendment to its existing Biologic License Application (BLA) in the fourth quarter of this year to gain licensure of PROVENGE.

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than one million men in the United States have prostate cancer, with an estimated 186,320 new cases and approximately 28,660 men who were expected to die from the disease in 2008. Currently there are limited treatment options for men with advanced, metastatic prostate cancer.

Conference Call Scheduled for Today at 9:00 a.m. ET

Dendreon will host a conference call today at 9:00 a.m. ET. To access the live call, dial 1-877-419-6594 (domestic) or 719-325-4855 (international). The call will also be audio webcast and will be available from the Company's website at www.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebro
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
3. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
4. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
5. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
6. Study Shows Machine Perfusion Significantly Improves Transplant Results
7. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
8. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
9. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
10. On the boil: New nano technique significantly boosts boiling efficiency
11. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Proove Biosciences , a commercial ... to announce the launch of their CME-accredited course ... of Pain”. , The continuing medical education program ... year. The focus of the program is to ... treatments, integrate appropriate pain management techniques, and incorporate ...
(Date:3/4/2015)... March 04, 2015 Follow us ... one of the fastest growing technologies in the life ... subcellular visualization is driving growth in nucleic acid detection ... understanding of gene expressions will continue to benefit the ... in fields ranging from pharma, biotech, food & beverage ...
(Date:3/3/2015)... - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a ... target the underlying mechanisms of cancer, today reported financial ... 31, 2014. Effective July 17, 2014, the ... to December 31. As a result of that change, ... quarter and the seven months ended December 31, 2014, ...
(Date:3/3/2015)... , March 3, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... million.  The orders are for odour control projects in ... and Asia . "Bidding activity in ... President and CEO. "After a high volume year for bidding in ... the New Year.  The recent orders reflect the organization,s renewed focus ...
Breaking Biology Technology:Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... , ... ... ... ...
... ... gives corn and soybean growers the opportunity to produce higher yields and stronger crops ... less pressure and improved yield potential. , ... Philadelphia, PA (PRWEB) March 9, 2010 -- As planting season ...
... ... for Best Industry-Exclusive Agency and Best Business Development Program for sanofi-aventis , ... Salem, MA ... pharmaceuticals focused strategic communications agency, announced today that it has won two 2009 ...
Cached Biology Technology:Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 2Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 3Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 4Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 5Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 6Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 7Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 8Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 9Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech 10Preemergence Herbicides from FMC Boost Early Season Plant Health in Corn and Soybeans and Help Optimize Yields for 2010 2Preemergence Herbicides from FMC Boost Early Season Plant Health in Corn and Soybeans and Help Optimize Yields for 2010 3LaVoie Group Honored by LACP with Two Awards 2LaVoie Group Honored by LACP with Two Awards 3LaVoie Group Honored by LACP with Two Awards 4
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... corporate website ( http://www.nxt-id.com/ ) as part of its ... wallet. The Company launched its new consumer website for ... Pereira , CEO of NXT-ID said, "Our new corporate ...
(Date:2/5/2015)... 28, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... Global Online CEO Conference on January 29 th ... Pereira , CEO of NXT-ID will present and host ... Wocket smart wallet and its full suite of biometric ...
(Date:2/5/2015)... , Feb. 3, 2015 Despite a ... from industries such as consumer electronics, automotive, storage ... surface mount technology (SMT) screen printers. Innovations in ... control will push the adoption curve up. Meanwhile, ... steady as glue dispensers are indispensable in the ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
... When the forces of evolution took over an experimental strain ... researchers thought they were conducting, but led to something much ... mice raised in a large plastic bubble, called an isolator, ... introduced a single type of bacteria into the mouse colony, ...
... WI, May 18, 2010 Cover crops may be ... maize harvest than rough tillage, according to scientists from ... Independent Center for the Promotion of Forage (CIPF). ... by Eric Laloy, measured erosion and runoff losses from ...
... CA May 17, 2010 An international team of ... National Research Institute for Child Health and Development in Japan ... the progression of osteoarthritis. The findings could one day lead ... The study was published in an advanced, online issue of ...
Cached Biology News:Quickly evolving bacteria could improve digestive health 2Cover crops reduce erosion, runoff 2Team led by Scripps Research scientists discovers body's own molecular protection against arthritis 2Team led by Scripps Research scientists discovers body's own molecular protection against arthritis 3
... In Situ Apoptosis Detection Kit detects ... TUNEL method, utilizing an anti-digoxigenin antibody ... provides indirect immunofluorescence staining for 40 ... fluorescence microscopy or flow cytometry (requires ...
... a single-step staining method for labeling DNA ... cytometry. The kit contains all the key ... including: positive and negative control cells for ... buffers for processing individual steps in the ...
... The BioGenex VISION Sytem is a ... comes with proprietary digital imaging and ... digital image acquisition, analysis, archving/retrieval and ... comes with the industry's fastest scanning ...
... HV high-voltage power supply, with temperature probe, 100-120 ... 5,000 V, 500 mA, and 400 W. The ... between 0 and 90 degrees C during electrophoresis. ... Power cord and instructions are provided. Dimensions are ...
Biology Products: